TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from Microbot Medical ( (MBOT) ).
On September 8, 2025, Microbot Medical Inc. announced it received FDA 510(k) clearance for its LIBERTY® Endovascular Robotic System, marking a significant milestone in its commercialization efforts in the U.S. The company’s CEO, Harel Gadot, will discuss this development and its implications for redefining the peripheral endovascular space during a live interview on Benzinga All Access on September 24, 2025.
The most recent analyst rating on (MBOT) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on Microbot Medical stock, see the MBOT Stock Forecast page.
More about Microbot Medical
Microbot Medical Inc. is a pioneering medical device company specializing in endovascular procedures through advanced robotic technology. Their flagship product, the LIBERTY® Endovascular Robotic System, is the first single-use, remotely operated robotic solution designed to enhance precision, efficiency, and provider safety in medical procedures.
Average Trading Volume: 3,727,776
Technical Sentiment Signal: Buy
Current Market Cap: $150.8M
Find detailed analytics on MBOT stock on TipRanks’ Stock Analysis page.